Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.73 · Revenue $0.00 · 8 analysts
Est. EPS $-0.78 · Revenue $0.00 · 7 analysts
Est. EPS $-2.83 · Revenue $1.34M · 10 analysts
Est. EPS $-0.80 · Revenue $0.00 · 2 analysts
EPS €-0.70 · Revenue €0.00
EPS €-0.61 · Revenue €0.00
EPS €-2.97 · Revenue €0.00
EPS €-0.60 · Revenue €0.00
EPS €-0.83 · Revenue €0.00
EPS €-0.85 · Revenue €0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-175.7M | -30.9% | -20.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-137.2M | -13.7% | +23.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 0.3% | -11.0% | -28.4% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 10.11x | -19.8% | +6.2% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $301.5M | +3.5% | +26.5% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -2.97 vs -2.74 | -8.4% | -0.70 vs -0.65 | -7.2% |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Common Stock | D | 2,292 | $34.77 |
| Aug 12, 2026 | Lu Peng | officer: President | Common Stock | D | 117 | $34.42 |
| Aug 11, 2026 | Lu Peng | officer: President | Common Stock | D | 109 | $34.84 |
| Jul 13, 2026 | Modig Berndt | director, officer: Chief Executive Officer | Common Stock | D | 2,292 | $34.97 |
| Jul 12, 2026 | Lu Peng | officer: Chief Medical Officer | Common Stock | D | 117 | $35.07 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Berndt Axel Edvard Modig | Co-Founder, Chief Executive Officer & Executive Director | EUR 1,596,976 | Male | 1959 | Active |
Anna Nijdam | Head of Strategic Finance & Principal Accounting Officer | — | Female | 1981 | Active |
Anne Lesage | Chief Early Development Officer | — | — | 1961 | Active |
Maryann Cimino | Director of Corporate Relations | — | — | — | Active |
Wim Souverijns | Chief Commercial Officer | — | Male | 1971 | Active |
Peng Lu | President | — | — | 1978 | Active |
Annick Deschoolmeester | Chief Human Resources Officer | — | Female | 1973 | Active |
David W. Nassif | Chief Financial Officer, Chief Legal Officer & Corporate Secretary | — | Male | 1954 | Active |
Stefan Abele | Chief Technology Operations Officer | — | — | 1970 | Active |
5AM Venture Management LLC bought a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 797,600 shares of the company's stock, valued at approximately $27,581,008,000. Pharvaris makes up approximately 9.6% of 5AM Venture Management
ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the second quarter ending on June 30, 2026, and provided a business update.
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that results from the first in-depth qualitative study assessing the experiences of people with AAE-C1INH and validating relevant patient-reported outcome (PRO) measures have been published in Frontiers in Immunology. The study findings directly informed the design of and endpoint selection for the ongoing Phase 3 CREAATE study (NCT07266805) investigating deucrictibant for the prophylaxis and on-demand treatment of AAE-C1INH attacks.
Pharvaris is positioned to build a vertically integrated HAE franchise with deucrictibant in both immediate-release (IR) and extended-release (XR) forms. PHVS's NDA for deucrictibant IR was accepted by the FDA, with a PDUFA date set for April 23, 2027, following strong Phase 3 RAPIDe-3 results. The CHAPTER-3 Phase 3 data for deucrictibant XR, expected Q3 2026, is the pivotal catalyst determining PHVS's potential as an end-to-end HAE platform.
The consensus price target hints at a 43% upside potential for Pharvaris (PHVS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
